Short Interest in Exscientia plc (NASDAQ:EXAI) Declines By 9.7%

Exscientia plc (NASDAQ:EXAI) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 2,890,000 shares, a decrease of 9.7% from the September 15th total of 3,200,000 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily volume of 676,600 shares, the short-interest ratio is presently 4.3 days.

Exscientia Price Performance

Shares of EXAI stock traded down $0.23 during trading hours on Thursday, hitting $5.06. 577,434 shares of the company’s stock were exchanged, compared to its average volume of 644,563. Exscientia has a 52 week low of $3.80 and a 52 week high of $7.91. The stock has a market cap of $611.69 million, a price-to-earnings ratio of -3.86 and a beta of 0.84. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The stock’s 50-day moving average is $5.14 and its 200-day moving average is $5.06.

Exscientia (NASDAQ:EXAI) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. The company had revenue of $5.60 million for the quarter. As a group, research analysts forecast that Exscientia will post -1.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on EXAI shares. TD Cowen reiterated a “hold” rating on shares of Exscientia in a research note on Friday, August 9th. Barclays reiterated an “equal weight” rating and issued a $5.00 price target on shares of Exscientia in a research report on Tuesday, August 13th.

Institutional Trading of Exscientia

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after purchasing an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Exscientia by 76.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company’s stock worth $53,000 after buying an additional 4,029 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in Exscientia in the second quarter valued at approximately $54,000. Federated Hermes Inc. bought a new position in Exscientia in the second quarter valued at approximately $115,000. Finally, EntryPoint Capital LLC grew its holdings in Exscientia by 22.8% during the 1st quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after acquiring an additional 5,784 shares during the period. Institutional investors and hedge funds own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.